Carla Casulo

6.3k total citations · 1 hit paper
95 papers, 1.9k citations indexed

About

Carla Casulo is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Carla Casulo has authored 95 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Pathology and Forensic Medicine, 50 papers in Oncology and 40 papers in Genetics. Recurrent topics in Carla Casulo's work include Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (40 papers) and Viral-associated cancers and disorders (28 papers). Carla Casulo is often cited by papers focused on Lymphoma Diagnosis and Treatment (82 papers), Chronic Lymphocytic Leukemia Research (40 papers) and Viral-associated cancers and disorders (28 papers). Carla Casulo collaborates with scholars based in United States, France and United Kingdom. Carla Casulo's co-authors include Jonathan W. Friedberg, Andrew D. Zelenetz, Jocelyn Maragulia, Richard Burack, Christopher R. Flowers, Brian K. Link, James R. Cerhan, Charles M. Farber, Xiaolei Zhou and John D. Hainsworth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Carla Casulo

90 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

2015 509 citations Carla Casulo, Michelle Byrtek et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carla Casulo United States	19	1.3k	1.1k	555	400	257	95	1.9k
Ayoma D. Attygalle United Kingdom	22	1.3k 1.0×	885 0.8×	324 0.6×	469 1.2×	149 0.6×	83	2.0k
Janet Matthews United Kingdom	21	1.6k 1.2×	1.2k 1.1×	695 1.3×	636 1.6×	206 0.8×	48	2.2k
William Townsend United Kingdom	22	897 0.7×	877 0.8×	365 0.7×	375 0.9×	187 0.7×	68	1.8k
José Rodríguez Spain	24	1.7k 1.3×	1.2k 1.1×	543 1.0×	553 1.4×	317 1.2×	64	2.1k
Pauline Brice France	23	2.3k 1.7×	1.4k 1.3×	546 1.0×	474 1.2×	722 2.8×	75	3.1k
Luís Colomo Spain	25	1.9k 1.5×	1.6k 1.5×	501 0.9×	779 1.9×	317 1.2×	66	2.7k
R. Gregory Bociek United States	27	1.7k 1.3×	1.3k 1.2×	927 1.7×	420 1.1×	383 1.5×	119	2.9k
Anne Sonet Belgium	22	1.3k 1.0×	873 0.8×	589 1.1×	396 1.0×	396 1.5×	64	2.2k
Achiel Van Hoof Belgium	18	1.9k 1.5×	1.3k 1.2×	918 1.7×	339 0.8×	239 0.9×	33	2.6k
M. Dreyling Germany	16	1.2k 0.9×	773 0.7×	438 0.8×	137 0.3×	261 1.0×	22	1.3k

Countries citing papers authored by Carla Casulo

Since Specialization

Citations

This map shows the geographic impact of Carla Casulo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carla Casulo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carla Casulo more than expected).

Fields of papers citing papers by Carla Casulo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carla Casulo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carla Casulo. The network helps show where Carla Casulo may publish in the future.

Co-authorship network of co-authors of Carla Casulo

This figure shows the co-authorship network connecting the top 25 collaborators of Carla Casulo. A scholar is included among the top collaborators of Carla Casulo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carla Casulo. Carla Casulo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Casulo, Carla & Laurie H. Sehn. (2025). Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?. Blood. 146(15). 1782–1791.

Bock, Allison M., Raphael Mwangi, Yucai Wang, et al.. (2024). Defining primary refractory large B-cell lymphoma. Blood Advances. 8(13). 3402–3415. 7 indexed citations

Loh, Kah Poh, et al.. (2024). How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma. Blood. 145(3). 277–289. 5 indexed citations

Zent, Clive S., Andrea Baran, Patrick M. Reagan, et al.. (2023). Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia. Blood Advances. 7(11). 2496–2503. 6 indexed citations

Linton, Kim, Lena Specht, Astrid Pavlovsky, et al.. (2023). Personalised therapy in follicular lymphoma – is the dial turning?. Hematological Oncology. 42(6). e3205–e3205. 4 indexed citations

Strawderman, Myla, Patrick M. Reagan, Paul M. Barr, et al.. (2023). Healthcare Utilization Disparities of Adolescent and Young Adults Compared to the Older Lymphoma Population. Clinical Lymphoma Myeloma & Leukemia. 23(9). e260–e267. 1 indexed citations

Sherazi, Saadia, Scott McNitt, Carla Casulo, et al.. (2023). Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders. Journal of the American Heart Association. 12(6). e025786–e025786. 1 indexed citations

Trotman, Judith, et al.. (2023). Women in Lymphoma: A 4‐year journey in promoting gender equity. Hematological Oncology. 42(6). e3183–e3183. 1 indexed citations

McNitt, Scott, et al.. (2023). Risk of New-Onset Atrial Fibrillation Associated With Targeted Treatment of Lymphoma. JACC Advances. 2(8). 100602–100602. 1 indexed citations

10.

Casulo, Carla, Jesse G. Dixon, Fang‐Shu Ou, et al.. (2021). Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances. 5(6). 1737–1745. 3 indexed citations

11.

Williams, AnnaLynn M., Andrea Baran, Patrick M. Reagan, et al.. (2020). Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. Leukemia & lymphoma. 62(3). 598–605. 1 indexed citations

12.

Casulo, Carla, et al.. (2019). Follicular Lymphoma. Hematology/Oncology Clinics of North America. 33(4). 627–638. 8 indexed citations

13.

Casulo, Carla, Armando Santoro, Kiyoshi Ando, et al.. (2019). Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial. Blood. 134(Supplement_1). 5320–5320. 13 indexed citations

14.

Williams, AnnaLynn M., Andrea Baran, Carla Casulo, et al.. (2018). Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. Clinical Lymphoma Myeloma & Leukemia. 19(1). 41–47. 18 indexed citations

15.

Williams, AnnaLynn M., Andrea Baran, Carla Casulo, et al.. (2017). Increased Risk of Toxicity with Novel PI3K Delta Inhibitor Combinations Compared with Standard Use in Non-Hodgkin Lymphoma Patients. Blood. 130. 4050–4050. 1 indexed citations

16.

Bates, James E., Sughosh Dhakal, Ali Mazloom, Carla Casulo, & Louis S. Constine. (2017). Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database. Radiotherapy and Oncology. 124(2). 325–330. 2 indexed citations

17.

Hunter, Bradley D., Megan M. Herr, Ferdous M. Barlaskar, et al.. (2016). Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma Myeloma & Leukemia. 17(3). 145–151. 9 indexed citations

18.

Zelenetz, Andrew D., Gilles Salles, Kylie D. Mason, et al.. (2016). Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology. 34(15_suppl). 7566–7566. 5 indexed citations

19.

Casulo, Carla, Michelle Byrtek, Keith Dawson, et al.. (2015). Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. Journal of Clinical Oncology. 33(23). 2516–2522. 509 indexed citations breakdown →

20.

Skalska, Jolanta, Carla Casulo, Paul S. Brookes, et al.. (2014). Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach. Experimental Hematology. 43(2). 89–99. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact